Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001

NCT06846541 is registered in ClinicalTrials.gov with Alumis Inc as lead sponsor.

NCT NCT06846541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06846541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Extension Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Long-term Safety, Efficacy, and Durability of Response to ESK-001
Lead sponsor
Alumis Inc
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 8, 2025
Completion date
November 30, 2028
Enrollment
1,680 (estimated)
Sites
268

Conditions

As the registry lists them; a condition with its own page is linked.

moderate psoriasis, plaque psoriasis, psoriasis, psoriasis (pso), severe psoriasis